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Background: Chemoprophylaxis is recommended for at-risk travellers visiting malaria endemic regions. The
majority of travellers with imported malaria have not used this, and travellers visiting friends and relatives have the
largest burden of malaria and the lowest compliance to chemoprophylaxis. In 1995, the UK’s Department of Health
(DH) implemented a policy to make travellers fully responsible for the cost when purchasing chemoprophylaxis.
This policy was not implemented in three Primary Care Trusts (PCTs) in London due to concern about the potential
increase of imported malaria in their residents, and they maintained the public subsidy. An impact evaluation of the
policy change was undertaken to determine if the continued subsidy reduced the incidence of imported malaria in
one of the boroughs where the subsidy was maintained when compared to a borough where no subsidy was
provided.
Methods: Between 2007 and 2010 prescriptions for malaria chemoprophylaxis were collected from pharmacy
records and PCTs, and all cases of imported malaria reported from the tertiary hospital in each of the two boroughs
were compared.
Results: The dispensed chemoprophylaxis prescriptions were nearly 8.8 times higher in Lambeth (where subsidized
drugs were provided), than in Hackney. A Poisson model revealed significantly fewer reports of imported malaria
per capita were made in Lambeth compared to Hackney (p = 0.042).
Conclusions: The difference in malaria reports between the boroughs only just reached statistical significance,
despite the considerable difference in chemoprophylaxis prescribing between the boroughs. Some travellers may
not consider using chemoprophylaxis, irrespective of the cost. Regular evaluations of the recent policy changes in
areas where malaria is subsidized will be important.
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The use of appropriate chemoprophylaxis before travel
to a malarious area is a key recommendation from the
World Health Organization (WHO) for malaria preven-
tion for at-risk travellers [1]. Atovaquone proguanil
(AP), mefloquine and doxycycline are the three
recommended regimens for sub-Saharan Africa and are
advised by national and international bodies for all tra-
vellers to malaria endemic countries within this region.* Correspondence: pneave@aut.ac.nz
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reproduction in any medium, provided the orHowever 64% of all malaria cases reported between 1999
and 2006 were in those who acquired malaria whilst
visiting friends and relatives (VFRs), and only 7% of
VFRs travelling to sub-Saharan Africa took malaria
chemoprophylaxis [2].
Recent research argues that AP is cost-effective com-
pared to the cost of malaria treatment for travellers to
West Africa [3]. Other estimates of the benefit of subsi-
dized chemoprophylaxis have been made using decision
tree models and data from imported cases, showing
costs and benefits in travellers. Pistone et al. examined
the likely impact of reimbursement in French residents
travelling, and argued that 2,485 cases and 13 malariaLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lers 65% of the costs of prophylactic drugs [4]. In
Switzerland, Widmer et al. used a similar method (deci-
sion tree model) with an enhanced sensitivity analysis on
levels of subsidy and levels of compliance to prophylaxis.
They calculated that if 55% of all travellers to West
Africa used mefloquine, and were reimbursed 82.4% of
its purchase cost, this would result in a 38% reduction of
imported malaria cases with a marginal increase in costs
to the health system [5].
In 1995, the UK’s Department of Health (DH) issued
regulations [6] that malaria chemoprophylaxis, previ-
ously available on National Health Service (NHS) pre-
scriptions, should no longer be subsidized [6]. The cost
of unsubsidized chemoprophylaxis for an adult visiting
sub-Saharan Africa for two weeks in 2009 (the middle
period of the research presented here) is shown in
Table 1.
In addition to the purchase costs, both General Practi-
tioners (GPs) and community pharmacists may charge
the patient for issuing and/or dispensing the private pre-
scription. Charges vary, both for GP and community
pharmacy. Following the policy change, concerns were
raised by healthcare professionals that the cost of
unsubsidized prescriptions may deter travellers from
purchasing chemoprophylaxis for all or some family
members [7] or that they may buy potentially ineffective
over-the-counter drugs [8-10].
Although DH guidance is usually followed, the Health
Authority in Lambeth, Southwark and Lewisham (LSL)
in South London decided not to implement the 1995
DH regulations, on advice from its Public Health
Department. These areas are home to relatively large
numbers of people of African origin, in particular those
from Nigeria and Ghana. Between 1987 and 2006, 54%
of all cases of imported malaria were in those who had
visited these countries [2]. The number of reports made
to the Malaria Reference Laboratory (MRL) from hospi-
tals within these boroughs is amongst the highest in the
UK [2]. It was decided that chemoprophylaxis would be
subsidized by the Health Authority, and it continued to
be available at the cost of an NHS prescription for resi-
dents of these boroughs. This ranged from GBP 6.65 inTable 1 Chemoprophylaxis costs and regimens for adults visi
Name of drug Dosage Start and length o
Mefloquine One tablet weekly 2-3 weeks before en
area, and four week
Atavaquone plus proguanil (AP) One tablet daily 1-2 tablets before e
area, and for one w
Doxycycline One tablet daily 1-2 days before ent
area, and four week
*retail prices are based on the profit margin suggested by the National Pharmacy A
**the most common duration of travel of patients reported to the MRL is 14 days (uApril 2006 to GBP 7.20 in April 2010. Residents in LSL
exempt from prescription charges would receive chemo-
prophylaxis at no cost to themselves.
Three studies carried out in different countries have
investigated whether the cost of chemoprophylaxis is a
deterrent to its use [11-13]. All reported that the cost of
these drugs was a concern for respondents. Although
this suggests that offering subsidized chemoprophylaxis
may prevent malaria cases, there has to date been no
evaluation of the policy of offering subsidized chemo-
prophylaxis in an area with a large African migrant
community.
Methods
Prescribing patterns for mefloquine and AP were com-
pared between two boroughs administrated by different
PCTs (the organisations which replaced Health Author-
ities and which manage the health of local populations).
As doxycycline may be prescribed for reasons other than
malaria chemoprophylaxis, prescriptions issued for this
drug were not included.
The boroughs chosen for comparison were broadly
similar with respect to key variables (Table 2) and were
amongst the ten most socio-economically deprived bor-
oughs in the country. The PCT governing Lambeth of-
fered subsidized malaria chemoprophylaxis, whereas
Hackney PCT followed the DH policy and required trav-
ellers to pay the full cost of chemoprophylaxis (Table 2).
It was hypothesized that there should be more pre-
scriptions issued in Lambeth than in Hackney. The ex-
pectation was that a higher uptake of chemoprophylaxis
amongst Lambeth residents would lead to a reduction in
imported cases of malaria in this area.
The PCTs governing Lambeth and Hackney were
asked for and provided the total number of subsidized
prescriptions for AP and mefloquine issued by each GP
surgery for the financial years 2007–2010. Each PCT also
provided contact email addresses for each community
pharmacy, which were asked to provide the numbers of
unsubsidized prescriptions for AP and mefloquine
dispensed between April 2007 and March 2010. Each
non-responder was contacted up to three times by
email and/or telephone. Counts of subsidized andting a malarious area in sub-Saharan Africa [7]
f administration Retail price 2009* Cost per traveller
for a 14 day visit**
tering a malarious
s after leaving
£29.06 for eight tablets £32.69
ntering a malarious
eek after leaving
£50.42 for 12 tablets £96.60
ering malarious
s after leaving
£3.52 for 28 100mg tablets £5.53
ssociation (personal communication A Tang, NPA).
npublished data from the MRL 2004–2008).
Table 2 Demographic characteristics of residents in Lambeth and Hackney PCTs
Hackney Lambeth
Mid-year population estimate 2008 and age categorization (%) 212,200 274,500
0-14: 44 000 (20.7) 0-14: 46 100 (16.8)
15-64:150 100 (70.7) 15-64: 205 100 (74.7)
65+: 18 200 (8.6) 65+: 23 100 (8.4)
Index of Multiple Deprivation ranking 2010* 2 29
Estimated number of residents of African ethnicity 21,200 23,900
Estimated number of residents born in Nigeria 2001 (%) 6,633 (3.1) 6,121 (2.2)
Estimated number of residents born in Ghana 2001 (%) 3,209 (1.5) 4,421 (1.6)
*i e Hackney was ranked the second most deprived borough in England and Lambeth was ranked the 29th from a total of 326 English boroughs [17].
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spreadsheet and exported into the statistical software
package “R” for analysis.
The MRL provided the number of reports of malaria
received from the largest hospitals situated in each bor-
ough. A Poisson model was used to test the difference in
the number of reports between the boroughs, adjusting
for population size.Results
Details were received of all subsidized prescriptions is-
sued for AP and mefloquine (n = 28 605) for the three
financial years 2007 to 2010 inclusive, for each GP prac-
tice in Lambeth (51 practices) and Hackney PCT (38
practices). Thus, the response rate was 100%.
In Hackney, 18/63 (29%) of pharmacies provided data
on the number of unsubsidized prescriptions issued,
whilst for Lambeth the response rate was 27/63 (43%)
giving an overall response rate of prescriptions issued by
pharmacies of 36%. A total of 2770 prescriptions were
dispensed between 2007 to 2010 by pharmacies in these
two areas. Of pharmacists who responded, 96% in Lam-
beth provided details of prescriptions issued in each of
the three years, whilst 93% of pharmacists in Hackney
gave this information (Table 3).
There were 3,203 prescriptions issued in Hackney and
28172 issued in Lambeth over the three years (Table 3).
Thus, there was an 8.8 fold increase in the number of
subsidized prescriptions issued in Lambeth. In Lambeth,
the more expensive AP was prescribed 70% more often
than the cheaper alternative, mefloquine.Table 3 Prescriptions issued in Hackney and Lambeth and MR
Hackney
Total number of
subsidized prescriptions
Total number of
unsubsidized
prescriptions
M
rep
April 2007-
March 2010
1,518 1,685 2
(AP: 748, Mefloquine 770) (AP: 688, Mefloquine: 997)Ninety six percent of the prescriptions issued in
Lambeth were subsidized, demonstrating that the majo-
rity of GPs adhered to the prescribing policy in this area.
Two Lambeth GPs surgeries in particular did not follow
the policy of subsidizing chemoprophylaxis, and around
two thirds 398/1085 (37%) of unsubsidized prescriptions
came from these. There was also some evidence that not
all Hackney GPs followed the policy in operation in their
area, and continued prescribing subsidized chemo-
prophylaxis. However, this came predominately from just
three practices which issued two thirds (995/1518) of
the subsidized prescriptions. This suggests that through-
out other areas of Hackney, issuing unsubsidized pre-
scriptions was the usual practice followed. All reports of
laboratory-confirmed malaria (n = 419) made to the
MRL for the financial years 2007 to 2010 inclusive were
analysed.
The Poisson model showed that there were statistically
significantly fewer reports of imported malaria per capita
in Lambeth than in Hackney (p = 0.042) (Table 4).
Discussion
This study investigated the impact of a policy of offering
subsidized malaria chemoprophylaxis in one borough of
London. Previous studies have argued, based on mod-
elled data, that subsidizing malaria chemoprophylaxis
would be cost effective and reduce malaria in VFR trav-
ellers [3-5]. Their findings are in contrast to this study
which noted a small reduction in numbers of malaria
cases when a public subsidy was provided for chemo-
prophylaxis. A rough estimate of the public subsidy of
drug costs over this study period was GBP 1.6 millionL reports (April 2007-March 2010)
Lambeth
RL
orts
Total number of
subsidized prescriptions
Total number of
unsubsidized
prescriptions
MRL
reports
02 27,087 1,085 217
(AP:16,988,Mefloquine:
10,099)
(AP: 784, Mefloquine 301)
Table 4 Cumulative incidence per 100,000 population for prescriptions and malaria reports (April 2007-March 2010)
Hackney Lambeth
All prescriptions MRL reports All prescriptions MRL reports
Rate per 100 000* Rate per 100 000 Rate per 100 000 Rate per 100 000
April 2007-March 2010 1,521.6 96.0 10,263.0 77.9*
* p = 0.042 Poisson model.
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AP was GBP 72,000. Even where patients with uncom-
plicated falciparum malaria (the most commonly ac-
quired type of malaria reported in these areas) are
managed as out-patients (as the majority are in
Lambeth) the public subsidy appears to have a very mar-
ginal cost saving in reduced malaria cases.
The assumption of previous cost-benefit studies is
that the cost of chemoprophylaxis determines uptake.
However, other factors are likely to impact on this.
For example, some VFRs might leave unused chemo-
prophylaxis for host friends and family in malarious
countries, rather than completing their course [13].
Alternative reasons for non- adherence include a
dislike of its taste or forgetfulness [13,14]. Recent re-
search carried out to explore the reasons for the rela-
tively high incidence of imported malaria in the
Nigerian and Ghanaian communities in London sug-
gests that not all residents who live in boroughs
where malaria chemoprophylaxis is subsidized are
aware of this policy [15]. Furthermore, a review of
the primary research undertaken to understand risk
factors for imported malaria in the African diaspora
identified that as well as the cost of malaria chemo-
prophylaxis, low perceptions of personal risk, a dis-
trust of non-African doctors, and problems associated
with accessing drugs at short notice, for example
when travelling to attend funerals were relevant [16].
Although the cost of chemoprophylaxis may be one
factor deterring some individuals from purchasing it,
at least some of those infected with imported malaria
may not have intended to use it, irrespective of the
cost. Multi-level health promotion campaigns are
likely to be more effective in reducing the burden of
imported malaria, rather than relying on a single cost
subsidy.
There were some potential biases in the study. The
numbers of reports made to the MRL from the largest
hospital in each borough were compared when measur-
ing the incidence of imported malaria. A more precise
alternative would have been postcode of residence of the
patient reported to the MRL but incomplete postcode
data restricted its use. Travellers may be registered with
GPs in boroughs different to their area of residence.
Thus, some GPs may follow the policy operated in the
borough in which they are located, rather than that ofthe area of residence of individual patients. Patients with
imported malaria may be transferred to the Hospital for
Tropical Diseases or other tertiary centres and so
reported to the MRL from outside the borough of pa-
tient residence, but transfers were likely to be similar in
both study areas.
The unsubsidized prescription data were incomplete
as only one third of community pharmacists provided
data, despite several reminders and there may be a
potential non-response bias. Reports were received
from pharmacies in all postcode areas in Hackney
and all but four in Lambeth. However, the area
deprivation levels in the areas of non-responders were
similar to those who did respond. One of the
strengths of this study was that details of all subsi-
dized prescriptions and malaria reports were received.
The study included data for three years only. A lon-
ger time frame may have yielded different findings.
Under-notification of malaria cases is estimated to be
around 38% in the London region [17] and may have
been different between the reporting hospitals.
Cumulative incidence rates were calculated, rather
than the more accurate incidence rates per person-time,
and it is possible that residents in one borough may
travel more frequently and for a longer duration than in
the other. No local data are available on borough-level
travel patterns, but there is no reason to suspect that
these differ by borough of residence.
Conclusions
This study found that subsidizing malaria chemo-
prophylaxis had a marginal impact on the rates of
imported malaria, but was less than might be expected,
given the substantial difference in the numbers of
subsidized prescriptions issued by each borough. The
possible biases in the study and likely alternative ex-
planations for the findings need to be taken into ac-
count when interpreting the results, but suggest there
is as yet no good evidence to support a policy for sub-
sidizing malaria chemoprophylaxis to reduce imported
malaria in London.
In October 2011 the policy in Lambeth changed, with
subsidized AP no longer being prescribed unless other
chemoprophylactic drugs are contraindicated [18]. Eva-
luations of this policy are necessary to determine their
benefit, impact and cost-effectiveness.
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